2007
DOI: 10.1158/0008-5472.can-06-4244
|View full text |Cite
|
Sign up to set email alerts
|

Divergent Mechanisms of Glucocorticoid Resistance in Experimental Models of Pediatric Acute Lymphoblastic Leukemia

Abstract: Cell line models of glucocorticoid resistance in childhood acute lymphoblastic leukemia (ALL) almost invariably exhibit altered glucocorticoid receptor (GR) function. However, these findings are incongruous with those using specimens derived directly from leukemia patients, in which GR alterations are rarely found. Consequently, mechanisms of glucocorticoid resistance in the clinical setting remain largely unresolved.

Help me understand this report
View preprint versions

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

9
108
1

Year Published

2007
2007
2023
2023

Publication Types

Select...
7

Relationship

1
6

Authors

Journals

citations
Cited by 107 publications
(119 citation statements)
references
References 45 publications
9
108
1
Order By: Relevance
“…PDX cells were prepared for in vitro culture as described previously. 56 Lineage subtype and other details of PDXs and cell lines are shown in Table 1.…”
Section: Patients Materials and Methodsmentioning
confidence: 99%
See 3 more Smart Citations
“…PDX cells were prepared for in vitro culture as described previously. 56 Lineage subtype and other details of PDXs and cell lines are shown in Table 1.…”
Section: Patients Materials and Methodsmentioning
confidence: 99%
“…57 In vitro cytotoxicity assays In vitro drug sensitivity was assessed using the colorimetric methyl-thiazolyl-tetrazolium (MTT) assay, and is described elsewhere. 56 The cells were exposed to etoposide (Sigma-Aldrich, #E1383), vorinostat (donation from Merck Research Laboratories), terameprocol (donation from Erimos Pharmaceuticals) or an equivalent volume of dimethyl sulfoxide (DMSO) vehicle (Sigma-Aldrich).…”
Section: In Vitro Cell Culturementioning
confidence: 99%
See 2 more Smart Citations
“…Xenografts were previously established from direct patient explants (36) and are representative of BCP-ALL and T-ALL derived from patients with diverse treatment outcomes (see supplemental Table S1). Xenograft cells were retrieved from cryostorage and prepared for in vitro culture as described previously (37).…”
Section: Methodsmentioning
confidence: 99%